151 related articles for article (PubMed ID: 38132099)
1. RL2 Enhances the Elimination of Breast Cancer Cells by Doxorubicin.
Wohlfromm F; Seyrek K; Ivanisenko N; Troitskaya O; Kulms D; Richter V; Koval O; Lavrik IN
Cells; 2023 Dec; 12(24):. PubMed ID: 38132099
[TBL] [Abstract][Full Text] [Related]
2. Lactaptin induces p53-independent cell death associated with features of apoptosis and autophagy and delays growth of breast cancer cells in mouse xenografts.
Koval OA; Tkachenko AV; Fomin AS; Semenov DV; Nushtaeva AA; Kuligina EV; Zavjalov EL; Richter VA
PLoS One; 2014; 9(4):e93921. PubMed ID: 24710119
[TBL] [Abstract][Full Text] [Related]
3. Interplay Between Mitophagy and Apoptosis Defines a Cell Fate Upon Co-treatment of Breast Cancer Cells With a Recombinant Fragment of Human κ-Casein and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.
Wohlfromm F; Richter M; Otrin L; Seyrek K; Vidaković-Koch T; Kuligina E; Richter V; Koval O; Lavrik IN
Front Cell Dev Biol; 2020; 8():617762. PubMed ID: 33537307
[TBL] [Abstract][Full Text] [Related]
4. The Recombinant Fragment of Human κ-Casein Induces Cell Death by Targeting the Proteins of Mitochondrial Import in Breast Cancer Cells.
Richter M; Wohlfromm F; Kähne T; Bongartz H; Seyrek K; Kit Y; Chinak O; Richter VA; Koval OA; Lavrik IN
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486420
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of Lactaptin.
Nemudraya AA; Makartsova AA; Fomin AS; Nushtaeva AA; Koval OA; Richter VA; Kuligina EV
PLoS One; 2016; 11(8):e0160980. PubMed ID: 27513518
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
[TBL] [Abstract][Full Text] [Related]
7. Nucleic Acids Delivery Into the Cells Using Pro-Apoptotic Protein Lactaptin.
Chinak O; Golubitskaya E; Pyshnaya I; Stepanov G; Zhuravlev E; Richter V; Koval O
Front Pharmacol; 2019; 10():1043. PubMed ID: 31619993
[TBL] [Abstract][Full Text] [Related]
8. Selection of antitumor displayed peptides for the specific delivery of the anticancer drug lactaptin.
Nemudraya AA; Kuligina EV; Ilyichev AA; Fomin AS; Stepanov GA; Savelyeva AV; Koval OA; Richter VA
Oncol Lett; 2016 Dec; 12(6):4547-4555. PubMed ID: 28105163
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468.
Natarajan S; Ranganathan M
Immunopharmacol Immunotoxicol; 2020 Oct; 42(5):408-415. PubMed ID: 32686546
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptin.
Koval OA; Sakaeva GR; Fomin AS; Nushtaeva AA; Semenov DV; Kuligina EV; Gulyaeva LF; Gerasimov AV; Richter VA
J Cancer Res Ther; 2015; 11(2):345-51. PubMed ID: 26148598
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and Antitumor Activity of Lactaptin in Combination with Autophagy Inducers and Inhibitors.
Bagamanshina AV; Troitskaya OS; Nushtaeva AA; Yunusova AY; Starykovych MO; Kuligina EV; Kit YY; Richter M; Wohlfromm F; Kähne T; Lavrik IN; Richter VA; Koval OA
Biomed Res Int; 2019; 2019():4087160. PubMed ID: 31317028
[TBL] [Abstract][Full Text] [Related]
14. A novel pro-apoptotic effector lactaptin inhibits tumor growth in mice models.
Koval OA; Fomin AS; Kaledin VI; Semenov DV; Potapenko MO; Kuligina EV; Nikolin VP; Nikitenko EV; Richter VA
Biochimie; 2012 Dec; 94(12):2467-74. PubMed ID: 22968174
[TBL] [Abstract][Full Text] [Related]
15. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
16. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
18. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
Chiu CF; Lin YQ; Park JM; Chen YC; Hung SW; Chiu CC; Chang CF
Biomed Pharmacother; 2020 Aug; 128():110309. PubMed ID: 32505820
[TBL] [Abstract][Full Text] [Related]
19. Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study.
Elia SG; Al-Karmalawy AA; Nasr MY; Elshal MF
J Biochem Mol Toxicol; 2022 Jan; 36(1):e22938. PubMed ID: 34719826
[TBL] [Abstract][Full Text] [Related]
20. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
Al-Momany B; Hammad H; Ahram M
Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
